340B Clinical Insights

Clinical Insights: October 19, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Menveo® (meningococcal conjugate vaccine) – New Label Expansion – October 14, 2022 – GSK plc announced that the US Food and Drug Administration…

Read More...

Clinical Insights: October 12, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Furoscix® (furosemide injection) – New Drug Approval – October 11, 2022 – The FDA has approved scPharmaceuticals’ Furoscix® (furosemide injection) for treatment of congestion due to fluid overload in…

Read More...

Clinical Insights: October 5, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Lytgobi® (futibatinib) Tablets – New Drug Approval – September 30, 2022 – The Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi®, Taiho Oncology, Inc.) for adult patients…

Read More...

Clinical Insights: September 28, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Pedmark® (sodium thiosulfate) – New Drug Approval – September 20, 2022 – On September 20, 2022, the Food and Drug Administration approved sodium thiosulfate (Pedmark®, Fennec Pharmaceuticals Inc.) to…

Read More...

Clinical Insights: September 21, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Skysona® (elivaldogene autotemcel) Suspension for Intravenous Infusion – New Drug Approval – September 16, 2022 – bluebird bio, Inc. announced the U.S. Food and Drug Administration (FDA) has granted…

Read More...

Clinical Insights: September 14, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Sotyktu™ (deucravacitinib) Tablets – New Drug Approval – September 9, 2022 – Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class,…

Read More...

Clinical Insights: September 7, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Konvomep™ (omeprazole and sodium bicarbonate) Powder for Oral Suspension – New Drug Approval – September 2, 2022 – Azurity Pharmaceuticals, Inc., a pharmaceutical company focused on developing innovative dose-forms…

Read More...

Clinical Insights: August 31, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Pemazyre® (pemigatinib) – New Drug Approval – August 29, 2022 – The Food and Drug Administration approved pemigatinib (Pemazyre®, Incyte Corporation) for adults with relapsed or refractory myeloid/lymphoid neoplasms…

Read More...

Clinical Insights: August 24, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Auvelity™ (dextromethorphan and bupropion) Extended-Release Tablets – New Drug Approval – August 19, 2022 – Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management…

Read More...

Clinical Insights: August 17, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Tabrecta® (capmatinib) Tablets – New Expanded Label – August 10, 2022 – The Food and Drug Administration granted regular approval to capmatinib (Tabrecta®,…

Read More...

Clinical Insights: August 10, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Kyzatrex™ (testosterone undecanoate) Capsules – New Drug Approval – August 2, 2022 – Marius Pharmaceuticals, a patient-centric healthcare company, announced the approval of Kyzatrex™ (testosterone undecanoate) by the U.S….

Read More...

Clinical Insights: July 27, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage July 26, 2022 Daptomycin Injection (Discontinuation) Doxepin Hydrochloride Oral Solution (Discontinuation) Gentamicin Sulfate Injection (Currently in Shortage)…

Read More...